Barclays
PCVX icon

Barclays’s Vaxcyte PCVX Stock Holding History

Barclays’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$3.42M – 5192
2024
Q1 		$3.42M Buy
+50,000
New +$3.46M ﹤0.01% 2117

Other funds holding PCVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Barclays's PCVX Position: Q3 2026 in Review

Barclays increased its Vaxcyte (PCVX) stake by 322% in Q3 2026, buying an estimated $7.33M and bringing the position to 164,801 shares worth $9.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

Barclays first reported a position in PCVX in Q1 2022 and has held it in 19 quarters since. The position peaked at $24M in Q3 2024. 127 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Barclays held 164,801 shares of Vaxcyte worth $9.38M as of Q3 2026.
  • Barclays bought 125,748 Vaxcyte shares in Q3 2026, an estimated $7.33M.
  • Vaxcyte made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1680 holding.
  • Barclays first reported a position in Vaxcyte in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Vaxcyte position peaked at $24M in Q3 2024.
  • 127 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.